Merck Acquires Chord Therapeutics to Expand Neuroinflammatory Pipeline
Chord Therapeutics was launched by Omega Funds in October 2020 to develop new oral treatments for rare neuroinflammatory diseases
Merck to accelerate development of Chord's innovative pipeline for generalized Myasthenia Gravis (gMG) and Neuromyelitis Op... Biopharmaceuticals, Neurology, Mergers & Acquisitions Chord Therapeutics, Merck
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Brain | Merck | Mergers and Aquisitions | Myasthenia Gravis | Neurology | Pharmaceuticals